By Anna Gillio Tos, Alessandro Cignetti, Giovanni Rovera, and Robin Foa Tumor necrosis factor a (TNFa) may induce tumor cell death by apoptosis, the physiologic program of cell death usually lost during neoplastic progression. However, many tumor cells are resistant to its effect unless high doses are administered. By retroviral vector-mediated gene transfer, we have transduced the TNFa gene into the DNA of human tumor cells t o investigate whether the indefinite neoplastic cell proliferation could be blocked and the lost physiologic program of cell death restored. Evidence is provided that high-TNFaproducing clones generated from a human lymphoma T-cell line (ST41 can undergo apoptosis following transduction of the TNFa gene. lnternucleosomal DNA cleavage was documented by May-Grlinwald-Giemsa and by propidium iodide staining, as well as by gel electrophoresis. The induced apoptotic phenomenon is TNFa-mediated, since it can be reverted following incubation with anti-TNFa monoclonal antibodies (MoAbs), and it occurs with cytokine levels re-UMOR NECROSIS FACTOR a (TNFa) is a monocytederived cytotoxin with contrasting effects in higher organisms: it can protect against infection and induce tumor regression, but it can also cause septic shock, inflammatory disease, and cachexia."' TNFa was first described as a direct cytolytic effector on cancer cells, since it was found to be capable of inducing spontaneous tumor regressions in neoplastic patients usually in association with an infective episode. Experimental models have documented the remarkable antineoplastic activity of TNFa: studies both in vitro and in vivo (in murine models) have emphasized the selective direct effects of TNFa on transformed cells and its capacity to activate the host immune system4 by enhancing cytotoxic activities mediated by monocytes,' polymorphonuclear cells,6 T lymphocytes: and natural killer' and lymphokineactivated killer' effectors. These findings led to consideration of this cytokine as a potentially most promising tool for the treatment of patients with cancer. However, its clinical use leased in the supernatant by the engineered cells much lower (>l00 times) than those required t o promote the same effect on parental ST4 cells following administration of exogenous recombinant TNFa. The process is associated with a downregulation of the apoptosis-preventing gene, bcl-2, while the expression of bax and p53, genes usually involved in promoting apoptosis, persists. Mixed-culture experiments performed coincubating TNFa-transduced and untransduced ST4 cells allowed documentation of a bystander-killing effect on the parental cells. This phenomenon still occurred at transduced t o parental cell ratios as low as 1:20 and was blocked in the presence of an anti-TNFa MoAb. These findings indicate that TNFa may play a regulatory role in the proliferation of human tumor cells, and suggest potential new antitumor therapeutic strategies based on the direct delivery of the TNFa gene into cancer cells. 0 1996 by The American Society of Hematology.
in man has been greatly limited by the important toxicity associated with its systemic administration, which has prevented administration of doses of TNFa known to exert an antitumor effect in mice. In man, the maximal tolerated dose of TNFa (10 pg/kg) is approximately 40-fold less than the doses required to generate a significant antitumor response in mice (400 pglkg)."' This limitation may be circumvented by tumor cell-targeted gene therapy."~'' Tumor cells can, in fact, be genetically engineered to produce a given cytokine and, upon injection in vivo of the transduced cells, to provide locally a small but continuous cytokine concentration. Without systemic dispersion, the cytokine doses required to display an antitumor effect may be lower and the related toxicity consequently reduced.
It is currently unknown which is the sequence of events that takes place in the process of TNFa-mediated antitumor response. One of the mechanisms of action of TNFa on cancer cells has been shown to be induction of tumor cell death by apoptosis, suggesting a possible role for TNFa in the physiologic processes that control cell proliferation. It has been observed that TNFa can induce apoptosis in different cell types (hematopoietic cells,".l' fibroblasts," hepatocytes,I8 and mammary adenocarcinoma cells"), as documented by nuclear disintegration and cytoplasmic blebbing of the cells characteristic of the apoptotic phenomenon. However, several neoplastic cell populations are resistant to this effect,*" unless very high concentrations of the cytokine are used.
In the present study we investigated whether, following transduction of the TNFa gene into the DNA of human cancer cells, the indefinite proliferation could be blocked in the transformed cells and the lost physiologic program of cell death restored. Our data provide evidence of TNFainduced apoptosis in a human lymphoma T-cell line transduced with the TNFa gene. It is worth noting that the phenomenon occurs with concentrations of TNFa released by the engineered cells in the supernatant that are ineffective if administered exogenously to the parental cells. The apoptotic process is associated with a downmodulation of bcl-2 and is also induced through a bystander-killing effect in unmodified parental cells.
MATERIALS AND METHODS
Cell lines. ST4 is a human lymphoma T-cell line derived from a lymph node biopsy of a patient currently alive." ST4 expresses a cortical thymic phenotype (CDI', CD3-, CD7', CD87 and is growth factor-independent. ST4, the amphotropic virus-packaging AM12," and NIH-3T3 cell lines were cultured in vitro in RPM1 1640 medium (Celbio Laboratories, Opera, Italy), 10% fetal bovine serum, and antibiotics.
Reagents and antibodies. Highly purified human recombinant TNFa (rTNFa) was purchased from UBI (Lake Placid, NY). The ascitic anti-TNFa B154.2 monoclonal antibody (MoAb-l) was a kind gift from Dr G. Trinchieri (The Wistar Institute, Philadelphia, PA)." The purified anti-TNFa MoAb (MoAb-2) was provided by Biosource International (Camarillo, CA). MoAbs directed against the two chains of the TNFa receptor, htr-9 (anti-CD120a) and utr-1 (anti-CD120b),24 were kindly provided by Dr M. Brockhaus (Hoffmann-la Roche, Basel, Switzerland).
Flow cytometry. To examine the surface expression of TNFa and TNFa receptors, cells were incubated with the above MoAbs at 4°C for 20 minutes, rinsed, and labeled with fluorescein isothiocyanate-conjugated rabbit antimouse IgG (Becton Dickinson, Mountain View, CA) at 4°C for 20 minutes. The cells were then rinsed and analyzed on a FACScan (Becton Dickinson).
Nuclear DNA content was analyzed by flow cytometry as previously described.25 Briefly, cells were centrifuged, the cell pellet was gently resuspended in hypotonic fluorochrome solution (50 pg/ mL propidium iodide [PI] in 0.1 % sodium citrate containing 0.1% Triton X-IOO), and RNasi-A was added (0.5 mL of a I-mg/mL solution). Cells were then incubated at 4°C overnight in the dark. Fluorescence emitted from the PI-DNA complex was then quantified after laser excitation of the fluorescence dye by a FACScan.
Cell viability andproliferation. Viability was evaluated by staining the cells with a 10% trypan blue solution and counting them under a Biirker chamber: cells that completely excluded trypan blue were considered alive. To verify the morphologic appearance of characteristic apoptotic corpuscles in dying cells, cytospins were prepared and stained with May-Griinwald-Giemsa.
Cell proliferation was tested by ['HI-thymidine ('H-TdR) uptake assay. Cells were incubated for 2 days in a 96-well U-bottom plate in the presence of medium alone or increasing concentrations of rTNFa (10 pg/mL up to 5 pg/rnL), and then pulsed for 18 hours with 1 pCi/well 'H-TdR (specific activity, 5 Ci/mmol/L; Amersham International, Amersham, Bucks, UK). The cells were then harvested with an automatic cell harvester, and 3H-TdR incorporation was measured with a liquid scintillation counter.
Generation of recombinant retrovirus and viral infection. Briefly, an 800-bp EcoRI fragment was obtained from a plasmid, pSp64-TNF, that contained cDNA encoding for the direct expression of mature human TNFaZ6 and just a small portion of its leader sequence, sufficient to allow correct secretion of the cytokine. An 852-bp cDNA fragment encoding the herpes simplex virus thymidine kinase (TK) promoter was obtained from the pHSV-106 plasmid2' following digestion with the restriction enzymes B a d 1 and BgIII. The TK promoter-encoding cDNA fragment was fused to the T W a cDNA fragment, and this complex was cloned into a unique SnaBI site of the polylinker sited in the 3' LTR of the N2A retroviral vecto?* (kindly provided by Dr E. Gilboa, Duke University, Durham, NC), already containing a cDNA fragment of the neomycin resistance gene (NEO). All restriction enzymes were supplied by Boehringer (Mannheim, Germany). To convert this retroviral vector construct (pN2A-TNF) into the corresponding virus, the vector was transfected by lypofectionZ9 into a helper-free amphotropic viruspackaging cell line (AM12).22 AM12-TNF colonies were isolated by G418 (1 mg/mL; GIBCO-BRL, Gaithersburg, MD) selection and expanded into cell lines, and cell-free supernatants were tested for the presence of virus by the NIH-3T3 colony-forming units (CFU) assay, as previously described." The AMI2-TNF cell line that secretes the highest titer of virus (105 NE0 CFU/mL) was used to infect ST4 cells, as previously described.'"
Reverse transcriptase-polymerase chain reaction analysis. Total cellular RNA was extracted according to the method of Chomczynski and Sacchi" using RNAzol solution (CinnaBiotec, Houston, TX). cDNAs were prepared by reverse transcription at 42°C for 30 minutes in a 50-pL reaction mixture containing 2 pg total RNA, 0. in an anti-TNFa-coated tube. Fifty microIiters of the second-step reagent (anti-TNFa "'I) was added to each tube. After 16 hours of incubation at room temperature, the tubes were decanted and washed twice with 20% Tween 20. The tubes were counted in a gamma counter for 60 seconds. The standard curve was prepared by plotting the counts per minute on the ordinate against the standard concentration on the abscissa. TNFa concentrations were determined by interpolation of the counts per minute using a computer-assisted polynomial function. As reported by the manufacturer, this IRMA is specific for TNFa and does not cross-react with TNFP, interleukin (1L)-l, IL-2, and interferon a (IFNa), P, and y . Sensitivity of the kit is 5 pg TNFaImL.
TNFa bioassay. TNFa biologic activity was measured by L929 cytotoxic assay, as previously described:' using human rTNFa (UBI) as the standard.
Chromatin fragmentation assay. One X IO6 cells per sample were washed twice in phosphate-buffered saline and lysed in a lysis solution containing 50 mmol/L Tris-HCI, pH 8, IO mmolR. EDTA, 0.5% (wt/vol) N-laurosylsarcosine, and 0.5 mg/mL proteinase A.
After 1 hour of incubation at 5 0 T , the suspension was treated with 10 pL OS-mg/mL DNase-free RNase solution for 1 hour at 50°C. 
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Subsequently, a sample buffer previously incubated for 10 minutes at 70°C was added: this contained 10 mmol/L EDTA, pH 8, I % lowmelting-temperature agarose, 0.2% (wt/vol) bromophenol blue, and 40% (wt/vol) saccharose. Samples were then separated by electrophoresis in Trishoric acidEDTA on a 2% agarose gel in the presence of ethidium bromide.
Bystander-killing efect. Mixed cultures were set up in vitro coincubating for 8 days in a 24-well flat-bottom plate the TNFatransduced ST4 cells with the unmodified parental ST4 cells at different ratios (1 : 1 to 1: 100) in the presence or absence of an anti-TNFa MoAb. Cells were checked daily for viability, and apoptotic cell death was assessed by May-Griinwald-Giemsa and PI staining.
RESULTS
Sensitivity of the ST4 cell line to exogenous TNFa. The sensitivity of ST4 to exogenous rTNFa was assessed in a proliferation test by 'H-TdR uptake. No variation in the proliferative rate was observed by adding rTNFa concentrations ranging between 10 and 500 pg/mL to 2.5 X l @ ST4 cells/ mL; a slight decrease was seen when rTNFa concentrations between 1 and 500 ng/mL were added, but a statistically significant ( P < .005) dose-dependent decrease in 'H-TdR uptake was seen only in the presence of rTNFa concentrations greater than 1 pg/mL (Fig l ) . Even in a viability assay, a cytotoxic effect on ST4 cells could be documented only after incubation with rTNFa concentrations greater than 500 ng/mL (data not shown). These results indicate the overall resistance of ST4 cells to exogenous rTNFa, which exerts a toxic activity only if administered at extremely high doses. Flow cytometry analysis using the htr-9 (anti-CD120a) and utr-l (anti-CD120b) MoAbs showed that ST4 cells express on the cell surface only the low-affinity chain ( p 5 3 of the TNFa receptor, while the high-affinity chain (p75) is absent (data not shown).
TNFa expression and production b), ST4 cells qfter transduction ofthe TNFa gene. ST4 cells do not produce TNFa constitutively, nor do they express TNFa mRNA in a RT-PCR assay (Fig 2) . These cells were transduced with the human TNFa gene by retroviral vector-mediated gene transfer, following construction of a Moloney murine leukemia virus-based retroviral vector, pN2A-TNF (Fig 3) . A cDNA encoding only for the mature form of TNFa linked to a very small fragment of its leader sequence was cloned into the N2A retroviral vector; this allows identification in the transduced cells of the mRNA for TNFa as a product of retroviral transcription, since it is shorter than the genomic TNFa transcript. After infection of ST4 cells and 20 days' selection in G418 ( I mg/mL)-containing medium, an ST4-TNF bulk culture was established. ST4-TNF bulk cells expressed human TNFa mRNA by RT-PCR analysis (Fig 2) .
Culture supernatants collected after 72 hours' incubation of 1 X IOh/mL ST4-TNF bulk cells contained 20 pg/mL TNFa protein when tested with an IRMA assay; when as- For sessed in the L929 cytotoxic bioassay, the material proved biologically active. ST4-TNF bulk cells were cloned by limiting dilution. Of 50 clones obtained, 20 produced detectable levels of TNFa (collected and tested with an IRMA kit and confirmed again with the cytotoxic bioassay, as above) that ranged between 3 and 249 pg/mL ( Table l) . These concentrations did not decrease over a 2-month period. Using an anti-TNFa MoAb, the clones were analyzed by flow cytometry for the expression of TNFa on the cell surface. Only four of 20 TNFa-producing clones (ST4-TNF #12, #18, #35, and #36) showed an increased expression in comparison to the parental cells (negative control), quantifiable as a weak increase in fluorescence intensity of 20%, 4%, 5%, and 2%, respectively (data not shown). None of the TNFa-producing clones showed a modulation in surface expression of the TNFa receptor chains, the p55 remaining expressed as in parental cells and the p75 not being induced (data not shown).
Growth kinetic follow-up of ST4-TNF clones. The proliferative rate of representative ST4-TNF clones was evaluated over a 7-day culture period and compared with that of parental ST4 cells and ST4 cells transduced with the retroviral vector (N2A)28 lacking the TNFa gene, as a vector control. Cells were seeded at 2.5 X 104/well and checked every day for viability. No significant difference was seen between all these cultures. Thus, no correlation was observed between TNFa concentrations released in culture supernatants and the proliferative rate of individual clones. These data suggested that the productive insertion of the TNFa gene in ST4 cells did not significantly modify their proliferative pattern in comparison to untransduced parental cells. However, if the clones were left to grow in culture until a cell concentration of 2 to 2.5 X 106/mL was reached and overpassed, some of them underwent a "crisis" and started to die progressively. This occurred in clones showing the highest TNFa release, ST4-TNF #I8 (1 16 pg/mL TNFa), ST4-TNF #32 (249 pg/ mL), and ST4-TNF #36 (203 pg/mL). A growth kinetic follow-up study of ST4 and of these high-producing clones was set up by seeding cells at day 0 in scalar concentrations (1, 0.5, 0.25, 0.12, 0.06, and 0.03 X lo6 cells/mL) to assess their concentration and viability daily for 8 days. In Fig 4A, the growth kinetics of a representative high-producing clone, ST4-TNF #36, as compared with ST4 cells, is shown. In all ST4 cultures, cell concentrations progressively increased, reaching values as high as 7 X lo6 viable cells/mL even if the culture medium was never changed. When the medium was changed every 3 days, cell concentrations reached even higher values (up to 10 X lo6 viable celldml; Fig 4B) . In high-producing ST4-TNF clones, cells proliferated normally until a concentration of 2 to 2.5 X lo6 cells/mL was obtained; thereafter, the cells underwent a crisis, with subsequent cell death. When the medium was changed every 3 days, only cultures in which cell concentrations did not reach 2 to 2.5 X lo6 cells/mL had a growth advantage. Whenever the cultures reached this concentration, changing the medium could not prevent cell death. These findings indicate that cells from high-producing ST4-TNF clones were capable of growing normally in vitro until a threshold concentration of cellsand consequently of TNFa protein released in the culture Supernatant-was reached. The daily addition of anti-TNFa MoAbs to the cultures restrained their cell death, proving that the phenomenon is TNFa-dependent (Fig 5) . The same MoAbs did not affect the growth kinetics of unmodified ST4 cells used as a negative control (data not shown). TNFa concentrations accumulated in these culture supernatants (between 100 and 250 pg/mL) were much lower than those required for exogenous rTNFa to be cytotoxic against ST4 cells. Continuous release of even low amounts of the cytokine, made possible by transfer of the TNFa gene, enabled the generation of a cytotoxic effect.
Endogenous TNFa induces apoptosis in ST4-TNF clones. Since in a morphologic analysis at the moment of the crisis many cells of the ST4-TNF clones, as well as ST4 parental cells treated with very high doses of rTNFa (>500 ng/mL), presented the typical aspects of apoptotic cells (Fig 6A) such as integrity of the cell membrane, coupled with cytoplasmic blebbing and chromatin condensation in the characteristic apoptotic corpu~cles,3~ we assumed that the program of cell death triggered by the transduced TNFa gene was an apoptotic program. To prove this hypothesis, cell samples from the ST4 parental cell line and from ST4-TNF clones in critical phase were stained with a hypotonic solution containing PI and analyzed by flow cytometry.
This staining, which allows discrimination between apoptotic nuclei (appearing as a broad peak of hypodiploid DNA) and normal nuclei (appearing as a narrow peak of diploid DNA):' revealed the presence of an apoptotic peak only in the clones in crisis (Fig 6B) . A DNA analysis was also set up and allowed documentation of the appearance of a chromatin fragmentation ladder in clones in crisis, as further proof of an apoptotic event (Fig 6C) .
Expression in ST4-TNF clones of genes related to the phenomenon of apoptosis. Recently, genes whose expression can be related to the phenomenon of apoptosis have been the object of many studies. Within these, the protooncogene bcl-2 prevents programmed cell death when overexpressed, whereas only a weak bcl-2 expression is observed in cells undergoing apopt~sis~~-~'; bd6s3' and ~5 3~'~~~ genes have a role in promoting apoptosis, thereby balancing the effects of bcl-2. We thus investigated whether in our system these genes were expressed and whether their expression was modulated when crisis occurred in high-producing ST4-TNF clones. By RT-PCR analysis, constitutive bcl-2, bar, and p53 expression was found in ST4, ST4-N2A, ST4-TNF bulk, and ST4-TNF clones before crisis ( Fig  7A) . When crisis occurred, ie, when the threshold concentration of 2 to 2.5 X lo6 cells/mL was reached and overpassed, expression of bcl-2 (in terms of levels of mRNA present in cells harvested when the density of cells that excluded trypan blue was still 21.5 X 106/mL) markedly decreased in high-producing ST4-TNF clones, while expression of bax and p53 genes persisted (Fig 7B) . These findings paralleled at the molecular level what had already been observed in growthkinetics studies of ST4-TNF clones and correlated with the staining of the same samples with PI hypotonic solution and DNA fragmentation. Under the same culture conditions, crisis never occurred nor was a downmodulation of bcl-2 detected in low-producing ST4-TNF clones overpassing the threshold cell density (Fig 7C) . Exogenous M a at concentrations as high as 500 ng/mL was unable to induce a downmodulation of bcl-2 expression in parental ST4 cells. Only a 7-day incubation of ST4 parental cells (1 X 106/mL) with a daily dose greater than 500 n g / d exogenous TNFa gave rise to a marked reduction of bcl-2 expression (Fig 8) . TNFa-transduced ST4 cells were also capable of involving in an apoptotic death program unmodified ST4 parental cells, mixed-culture experiments were set up in vitro for 8 days incubating ST4-TNF high-producing clones together with parental cells at a 1:1 ratio (Fig 9) : all cells in this mixed culture died, while in the control culture ST4 parental cells grew exponentially. May-Griinwald-Giemsa and PI staining proved that cells in the mixed culture died of apoptosis (data not shown). Similar results were obtained with ratios as low as 1:20, and this bystander-killing effect was reverted in the presence of an anti-TNFa MoAb (Fig 10) . With ratios of 1:100, the phenomenon was not observed. 
ST4-TNF high-producing cells exert a bystander-killing effect on untransduced parental cells. To investigate if
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DISCUSSION
Based on preclinical studies, TNFa would appear to be one of the cytokines with most promising anticancer activity. However, the results of clinical trials have been largely disapp0inting,4".~' and in most instances, neoplastic cell populations have shown resistance to the doses of exogenous rTNFa that can be safely injected in man. Doses at which tumor cells may become susceptible to systemic administration of TNFa are invariably associated with unacceptable individual toxicity. Several hypotheses may be put forward to explain the partial resistance to rTNFa of numerous human tumor cell types and the overall different susceptibility of human and mouse neoplastic cells. In an attempt to ex- plain the documented resistance of the lymphoma T-cell line ST4 to concentrations of exogenous rTNFa as high as 500 ng/mL, surface expression of the TNFa receptor chains was analyzed. ST4 parental cells express only the low-affinity chain ( p 5 3 of the TNFa receptor, and the high-affinity chain ( p 7 3 is lacking. Transduction of the TNFa gene did not modify the expression of both TNFa receptor chains, suggesting that surface expression of this receptor complex is not involved in the enhanced susceptibility of ST4 transduced cells to TNFa. Results of the present study demonstrate that individual systemic toxicity to exogenous TNFa may be circumvented by tumor cell-targeted gene therapy, which provides the wanted antitumor effects through a constant and continuous release by the engineered cells of much lower levels of the cytokine. The retroviral vector-mediated transfer of the TNFa gene into the genomic DNA of ST4 cells was, in fact, capable of promoting an apoptotic program of cell death in the highest cytokine-producing clones. Concentrations of TNFa released by transduced clones (ranging between 100 and 250 pg/mL) that were sufficient to induce the phenomenon are much lower than those required to trigger an apoptotic signal with exogenous rTNFa (>500 ng/ mL).
Induction of apoptosis in human tumor cells following transduction of a cytokine gene is a challenging result toward the understanding and potential correction of the abnormal events that govern the genomic program of a neoplastic cell, and is an attempt to restore the physiologic mechanisms gone astray in the process of neoplastic transformation. Restoration of an apoptotic program in ST4-TNF high-producing clones appears to be TNFa-mediated, since it can be reverted in the presence of anti-TNFa MoAbs. The phenomenon is associated with a downmodulation in the expression of hcl-2, a gene capable of inhibiting the physiologic program of cell death,""s while doses of exogenous rTNFa as high as 500 ng/mL were incapable of affecting both the viability and the hcl-2 expression of ST4 cells. Since the expression of other genes (hax and p53) that are known to play a role in promoting the apoptotic p r o c e~s~~.~~ persists in ST4-TNF high-producing clones in crisis, it can be assumed that transduction of the TNFa gene may selectively influence expression of hcl-2. It is beyond the scope of this study to assess whether transfer of the TNFa gene directly influences hcl-2 gene expression, or whether downmodulation of hcl-2 is only one of a cascade of events that are likely to include activation of other genes that cooperate in the control of cell proliferation. The same cell line used in the present study has been transduced with other cytokine genes-IL-2, IL-4, IL-7, IFNy, etc.-and an apoptotic signal has never been observed (Cignetti et a15* and Cignetti and Gillio Tos, unpublished data, September 1995). This also occurred when ST4 cells were transduced with the gene for IFNy, a cytokine known to play an important role in the regulation of ST4 cell proliferation?
The potential therapeutic implications of our findings require that the apoptotic signal can be induced in the great majority, ideally the totality, of the neoplastic population. Mixed-culture experiments with transduced and nontransduced cells allowed us to document that apoptosis occurred not only in ST4 cells engineered to release TNFa, but also in unmodified parental ST4 cells. More relevantly, it was shown that a bystander-killing effect could be induced at ratios between ST4-TNF high-producing clones and parental ST4 cells as low as 1:20. The low ratio between transduced and nontransduced ST4 cells (coupled with the relatively low quantities of TNFa released by ST4-TNF high-producing clones) still capable of giving rise to apoptosis, and the discrepancy with the levels of exogenous rTNFa required to induce the same phenomenon, suggest that a more complex cascade of events may take place in the gene-transduced setting. Nonetheless, a specific implication of the TNFa released endogenously by the engineered cells was demonstrated by control experiments in the presence of an antiTNFa MoAb. It may be postulated that endogenously TNFa promotes the expression and secretion of further factor(s) capable of synergizing with TNFa and of boosting the apoptosis program. Investigations will need to be performed on supernatants harvested from ST4-transduced cells, in an attempt to recognize and characterize the nature of the putative factor(s).
Taken together, results of this study indicate that transduction of the TNFa gene into the DNA of a human lymphoma T-cell line can restore the physiologic cell death program lost by the neoplastic clone. The induced apoptotic process is mediated by TNFa released by the engineered cells, is achieved with cytokine levels over 100-fold less than those required to induce a lytic signal with exogenous rTNFa, and is associated with downregulation of the bcl-2 gene. The demonstration that TNFa produced by engineered cells acts directly on the neoplastic clone and that it is capable of promoting a strong bystander-killing effect on parental unmodified cells suggests that the possibility of a direct in vivo delivery of TNFa-transduced tumor cells into a cancer mass may represent a therapeutic strategy worthy of investigation for anatomically localized and reachable tumor sites, also in patients with a compromised immune system.
